Passage Bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Passage Bio (NASDAQ: PASG) said management will present and hold investor meetings at two upcoming conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference on Feb 26, 2026 (virtual; presentation 8:40 a.m. ET) and TD Cowen 46th Annual Health Care Conference on Mar 4, 2026 (Boston; presentation 1:50 p.m. ET).

A live webcast will be available on the company's Investors & Media page and a replay will be accessible for 30 days after each event.

Argus Feb 19 session

-0.55% close to close 0.2x rel. volume Open Argus

Details

News Market Reaction – PASG

On Feb 19, the day this news came out, PASG closed 0.55% below the previous close.

Data tracked by StockTitan Argus for the Feb 19 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:

Oppenheimer 36^th Annual Healthcare Life Sciences Conference
Format: Management will participate in a presentation and investor meetings
Date: Thursday, February 26, 2026
Presentation Time: 8:40 a.m. ET
Location: Virtual

TD Cowen 46^th Annual Health Care Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 4, 2026
Presentation Time: 1:50 p.m. ET
Location: Boston, MA

A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. 

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Passage Bio (PASG) present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?

Passage Bio will present on Thursday, February 26, 2026 at 8:40 a.m. ET. According to the company, management will conduct a presentation and investor meetings during the virtual conference and the session will be webcast on the company investor site.

How can investors watch the Passage Bio (PASG) presentations and for how long will replays be available?

Investors can watch a live webcast on the company's Investors & Media page; replays remain available for 30 days. According to the company, replay access begins after the presentation and will be hosted on investors.passagebio.com for one month.

When and where will Passage Bio (PASG) present at the TD Cowen 46th Annual Health Care Conference?

Passage Bio will present on Wednesday, March 4, 2026 at 1:50 p.m. ET in Boston. According to the company, management will offer a presentation and hold investor meetings at the TD Cowen conference with details posted on the investor website.

Will Passage Bio (PASG) management hold investor meetings at the conferences and what formats are planned?

Yes — management will participate in presentations and investor meetings at both events. According to the company, the Oppenheimer session is virtual and TD Cowen is in-person in Boston, with investor meetings scheduled alongside each presentation.

Where is the official place to find the Passage Bio (PASG) webcast and investor event details?

The official location is the company's Investors & Media page at investors.passagebio.com. According to the company, the site will host the live webcast and provide replay access and event specifics for 30 days after each presentation.

Does Passage Bio (PASG) expect the conference presentations to be available after the events?

Yes — a replay of each presentation will be available for 30 days following the event. According to the company, investors can access the replay on the investor website for one month after the conclusion of each conference presentation.